EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance

Jiyu Han, Weitian Liang, Kai Li

Frontiers in Cell and Developmental Biology · 02.02.2026 · 13

DOI: 10.3389/fcell.2025.1753180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 02.02.2026. Verfasst von Jiyu Han und 2 weiteren Autor:innen. Beteiligte Einrichtung: Editorial Department of "Progress of Anatomical Sciences", China Medical University Journal Center, Shenyang, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 264 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic resistance remains a major barrier to effective treatment in colorectal cancer (CRC), where the tumor microenvironment (TME) plays a pivotal role in modulating responses to chemotherapy, immunotherapy, and targeted therapies. This review synthesizes current evidence on how cellular and non-cellular TME components contribute to resistance mechanisms in CRC. Key immune cells, including T cells, macrophages, neutrophils, natural killer cells, dendritic cells, and myeloid-derived suppressor cells, orchestrate immunosuppressive networks that impair drug efficacy. For instance, regulatory T cells and M2-polarized macrophages promote chemoresistance via cytokine secretion and metabolic reprogramming, while neutrophils and myeloid-derived suppressor cells hinder immune checkpoint blockade through extracellular trap formation and T-cell exhaustion. Non-cellular elements, such as extracellular matrix remodeling, hypoxia-induced metabolic shifts, and dysregulated cytokines like IL-6 and TGF-β, further exacerbate resistance by fostering epithelial-mesenchymal transition and angiogenesis. Tables highlight specific molecular axes and therapeutic implications. By elucidating these interactions, this article underscores the potential of TME-targeted strategies, such as macrophage reprogramming, cytokine inhibition, and combination therapies, to overcome resistance and improve clinical outcomes in CRC patients. Future research should prioritize integrating TME biomarkers for personalized treatment approaches.

Schlagwörter

Stichwörter der Autor:innen

TIMETMEchemotherapycolorectal cancerdrug resistanceimmunotherapytargeted therapy

Autor:innen und Institutionen

  • Editorial Department of "Progress of Anatomical Sciences", China Medical University Journal Center, Shenyang, China.
  • Department of Intensive Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Oncology Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.

Zitieren

APA

Han, J., Liang, W., & Li, K. (2026). Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1753180

Vancouver

Han J, Liang W, Li K. Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance. Frontiers in Cell and Developmental Biology. 2026;13. doi:10.3389/fcell.2025.1753180

BibTeX
@article{Han2026,
  author = {Han, Jiyu and Liang, Weitian and Li, Kai},
  title = {Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcell.2025.1753180}
}
Kostenlos starten →